Intelligent Bio Solutions financials
$1.63−1.21%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '26 Jun 30 | Q3 '26 Mar 31 | Q2 '26 Dec 31 | Q1 '26 Sep 30 | Q4 '25 Jun 30 | Q3 '25 Mar 31 | Q2 '25 Dec 31 | Q1 '25 Sep 30 | Q4 '24 Jun 30 | Q3 '24 Mar 31 | Q2 '24 Dec 31 | Q1 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.1M | $896.8K | $1.1M | $843.9K | $728.9K | $607.5K | $872.3K | $727.8K | $823.8K | $764.1K | $796.1K |
| Gross profit | $536.6K | $535.4K | $459.7K | $518.3K | $335.6K | $341.4K | $223.1K | $346.8K | $815.6K | $178.5K | $199.2K | $232.3K |
| Gross margin | 46.8% | 50.5% | 51.3% | 46.6% | 39.8% | 46.8% | 36.7% | 39.8% | 112.1% | 21.7% | 26.1% | 29.2% |
| Operating income | -$4.0M | -$2.9M | -$2.6M | -$3.0M | -$3.1M | -$2.6M | -$2.3M | -$2.7M | -$2.8M | -$3.0M | -$2.1M | -$2.6M |
| Net income | -$3.9M | -$2.9M | -$2.7M | -$3.0M | -$3.1M | -$2.5M | -$2.2M | -$2.7M | -$2.8M | -$3.0M | -$2.0M | -$2.4M |
| Net margin | −341.0% | −269.9% | −298.6% | −268.3% | −366.2% | −349.0% | −370.3% | −307.9% | −382.5% | −361.5% | −257.8% | −304.6% |
| Diluted EPS | — | $-1.80 | $-2.82 | $-3.50 | $-1.90 | $-4.41 | $-4.96 | $-7.00 | $-8.85 | $-14.30 | $-20.70 | $-124.80 |
| EBITDA | -$3.7M | -$2.7M | -$2.3M | -$2.5M | -$2.9M | -$2.3M | -$1.9M | -$2.5M | -$2.8M | -$2.6M | -$1.9M | -$2.3M |
| Operating cash flow | -$3.2M | -$4.3M | -$1.6M | -$2.8M | -$2.2M | -$2.8M | -$2.3M | -$2.4M | -$2.9M | -$2.4M | -$2.9M | -$1.3M |
| Free cash flow | -$3.2M | -$4.3M | -$1.6M | -$2.9M | -$2.4M | -$2.8M | -$2.3M | -$2.4M | -$3.1M | -$2.4M | -$2.9M | -$1.3M |
| Diluted shares | — | 1.6M | 1.0M | 0.9M | 1.6M | 0.6M | 0.5M | 0.4M | 0.3M | 0.2M | 0.1M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.0M | $6.9M | $740.4K | $1.7M | $1.0M | $2.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $13.0K | $139.8K | $197.1K | $356.2K |
| Total assets | $11.9M | $14.9M | $17.7M | $10.0M | $8.2M | $9.6M |
| Total liabilities | $6.7M | $6.1M | $6.8M | $6.6M | $5.4M | $4.6M |
| Shareholders' equity | $5.3M | $8.8M | $10.9M | $3.4M | $2.8M | $4.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology